Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Study Overview: Regeneron Pharmaceuticals is conducting a Phase 1/2 study titled A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors. The study aims to evaluate the safety, tolerability, and optimal dosing of REGN7075 alone and in combination with cemiplimab, with or without chemotherapy, in patients with advanced solid tumors. This research is significant as it explores new treatment avenues for challenging cancer types.
Intervention/Treatment: The study tests REGN7075, an investigational drug administered via intravenous or subcutaneous injection, both alone and in combination with cemiplimab, a known cancer treatment. The goal is to assess the efficacy of these combinations in shrinking tumors and controlling cancer progression.
Study Design: This interventional study is non-randomized and follows a sequential intervention model without masking. The primary purpose is treatment-focused, aiming to determine the best therapeutic approach for advanced solid tumors.
Study Timeline: The study began on December 21, 2020, and is currently recruiting participants. The last update was submitted on June 24, 2025. These dates are crucial for tracking the study’s progress and anticipating future developments.
Market Implications: The ongoing study could significantly impact Regeneron’s stock performance, especially if the results demonstrate promising efficacy and safety profiles. Positive outcomes may boost investor confidence and position Regeneron favorably against competitors in the oncology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.